Erwin Ciechański

Dr. Erwin Ciechański

Medical University of Lublin, Lublin, Lubelskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JSJarosław Szponar
Jarosław Szponar
Erwin CiechańskiErwin Ciechański
Erwin Ciechański
MCMagda Ciechanska
Magda Ciechanska
JDJaroslaw Dudka
Jaroslaw Dudka
SMSławomir Mandziuk
Sławomir Mandziuk
Doxorubicin (DOX) has been widely used as a cytotoxic chemotherapeutic. However, DOX has a number of side effects, such as myelotoxicity or gonadotoxicity, the most dangerous of which is cardiotoxicity. Cardiotoxicity can manifest as cardiac arrhythmias, myocarditis, and pericarditis; life-threatening late cardiotoxicity can result in heart failure months or years after the completion of chemotherapy. The development of late cardiomyopathy is not yet fully understood. The most important question is how DOX reprograms the cardiomyocyte, after which DOX is excreted from the body, initially without symptoms. However, clinically overt cardiomyopathy develops over the following months and years. Since the 1980s, DOX-induced disorders in cardiomyocytes have been thought to be related to oxidative stress and dependent on the Fe/reactive oxygen species (ROS) mechanism. That line of evidence was supported by dexrazoxane (DEX) protection, the only Food and Drug Administration (FDA)-approved drug for preventing DOX-induced cardiomyopathy, which complexes iron. Thus, the hypothesis related to Fe/ROS provides a plausible explanation for the induction of the development of late cardiomyopathy via DOX. However, in subsequent studies, DEX was used to identify another important mechanism in DOX-induced cardiomyopathy that is related to topoisomerase 2β (Top2β). Does the Top2β hypothesis explain the mechanisms of the development of DOX-dependent late heart failure? Several of these mechanisms have been identified to date, proving the involvement of Top2β in the regulation of the redox balance, including oxidative stress. Thus, the development of late cardiomyopathy can be explained based on mechanisms related to Top2β. In this review, we highlight free radical theory, iron imbalance, calcium overload, and finally, a theory based on Top2β.

Verified
Journal Article
Open access
PDF file
JSJarosław Szponar
Jarosław Szponar
AGAgnieszka Gorska
Agnieszka Gorska
MOMarta Ostrowska-Lesko
Marta Ostrowska-Lesko
AKAgnieszka Korga-Plewko
Agnieszka Korga-Plewko
MTMichal Tchorz
Michal Tchorz
SMSławomir Mandziuk
Sławomir Mandziuk
Late cardiotoxicity is a formidable challenge in anthracycline-based anticancer treatments. Previous research hypothesized that co-administration of carvedilol (CVD) and dexrazoxane (DEX) might provide superior protection against doxorubicin (DOX)-induced cardiotoxicity compared to DEX alone. However, the anticipated benefits were not substantiated by the findings. This study focuses on investigating the impact of CVD on myocardial redox system parameters in rats treated with DOX + DEX, examining its influence on overall toxicity and iron metabolism. Additionally, considering the previously observed DOX-induced ascites, a seldom-discussed condition, the study explores the potential involvement of the liver in ascites development. Compounds were administered weekly for ten weeks, with a specific emphasis on comparing parameter changes between DOX + DEX + CVD and DOX + DEX groups. Evaluation included alterations in body weight, feed and water consumption, and analysis of NADPH2, NADP+, NADPH2/NADP+, lipid peroxidation, oxidized DNA, and mRNA for superoxide dismutase 2 and catalase expressions in cardiac muscle. The iron management panel included markers for iron, transferrin, and ferritin. Liver abnormalities were assessed through histological examinations, aspartate transaminase, alanine transaminase, and serum albumin level measurements. During weeks 11 and 21, reduced NADPH2 levels were observed in almost all examined groups. Co-administration of DEX and CVD negatively affected transferrin levels in DOX-treated rats but did not influence body weight changes. Ascites predominantly resulted from cardiac muscle dysfunction rather than liver-related effects. The study’s findings, exploring the impact of DEX and CVD on DOX-induced cardiotoxicity, indicate a lack of scientific justification for advocating the combined use of these drugs at histological, biochemical, and molecular levels.

Verified
Journal Article
Open access
PDF file
JSJarosław Szponar
Jarosław Szponar
Erwin CiechańskiErwin Ciechański
Erwin Ciechański
MOMarta Ostrowska-Lesko
Marta Ostrowska-Lesko
AGAgnieszka Gorska
Agnieszka Gorska
MTMichal Tchorz
Michal Tchorz
SMSławomir Mandziuk
Sławomir Mandziuk
The anticancer efficacy of doxorubicin (DOX) is dose-limited because of cardiomyopathy, the most significant adverse effect. Initially, cardiotoxicity develops clinically silently, but it eventually appears as dilated cardiomyopathy with a very poor prognosis. Dexrazoxane (DEX) is the only FDA-approved drug to prevent the development of anthracycline cardiomyopathy, but its efficacy is insufficient. Carvedilol (CVD) is another product being tested in clinical trials for the same indication. This study’s objective was to evaluate anthracycline cardiotoxicity in rats treated with CVD in combination with DEX. The studies were conducted using male Wistar rats receiving DOX (1.6 mg/kg b.w. i.p., cumulative dose: 16 mg/kg b.w.), DOX and DEX (25 mg/kg b.w. i.p.), DOX and CVD (1 mg/kg b.w. i.p.), or a combination (DOX + DEX + CVD) for 10 weeks. Afterward, in the 11th and 21st weeks of the study, echocardiography (ECHO) was performed, and the tissues were collected. The addition of CVD to DEX as a cardioprotective factor against DOX had no favorable advantages in terms of functional (ECHO), morphological (microscopic evaluation), and biochemical alterations (cardiac troponin I and brain natriuretic peptide levels), as well as systemic toxicity (mortality and presence of ascites). Moreover, alterations caused by DOX were abolished at the tissue level by DEX; however, when CVD was added, the persistence of DOX-induced unfavorable alterations was observed. The addition of CVD normalized the aberrant expression of the vast majority of indicated genes in the DOX + DEX group. Overall, the results indicate that there is no justification to use a simultaneous treatment of DEX and CVD in DOX-induced cardiotoxicity.

29 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KCKrystian Ciechański
Krystian Ciechański
Erwin CiechańskiErwin Ciechański
Erwin Ciechański
KKKrystyna Kłosowska-Kapica
Krystyna Kłosowska-Kapica
BSBarbara Skrzydło-Radomańska
Barbara Skrzydło-Radomańska
Background: Gastric cancer (GC) is the fifth most common malignancy worldwide. Early detection of precancerous conditions—atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia—is vital for surveillance. Objectives: To assess the accuracy of single high-quality endoscopy (HQE) in detecting advanced GPCs and to identify risk factors for AG, IM, and dysplasia. Methods: A retrospective review of 442 gastroscopies (2017–2022) at a single center. Endoscopic findings were compared with histology, including OLGA/OLGIM staging, dysplasia, and Helicobacter pylori (H. pylori) status. Results: The study population comprised 319 women (72.17%) and 123 men (27.83%), with a mean age of 59 years (SD: 12.53). AG, as defined by OLGA and OLGIM staging, was identified in 90 patients (20.36%) and 50 patients (11.31%), respectively. A total of 44 cases of de novo gastric dysplasia were observed, while HP infection was confirmed in 37 individuals (8.37%). We observed similar low sensitivity for detection of advanced OLGA (32.5%), OLGIM (40%), and dysplasia (19.7%) with relatively high specificity (~89%). Advanced AG and IM peaked at ages 51–53. Risk factors for advanced OLGIM included male sex (OR 2.26; p < 0.001) and presence of dysplasia (OR 2.09; p = 0.02). Dysplasia was positively associated with AG (OR 2.03; p < 0.001) and IM (OR 2.21; p < 0.001) but inversely associated with a family history of GC (OR 0.44; p < 0.001). Conclusions: A single HQE can help exclude advanced GPCs, but due to low sensitivity, gastric mapping biopsies remain crucial. Males are at increased risk of extensive IM. Family history of GC was linked to lower OLGA/OLGIM stages.

28 April 2023 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
PDPiotr Denysiuk
Piotr Denysiuk
Erwin CiechańskiErwin Ciechański
Erwin Ciechański
TKTomasz Klecha
Tomasz Klecha
ADAdrianna Denysiuk
Adrianna Denysiuk
GGGerard Grossmann
Gerard Grossmann
PBPiotr Błaszczak
Piotr Błaszczak
W w w. j o u r n a l s. v i a m e d i c a. p l / k a r d i o l o g i a _ p o l s k a 414

18 August 2023 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
Erwin CiechańskiErwin Ciechański
Erwin Ciechański
PDPiotr Denysiuk
Piotr Denysiuk
KCKrystian Ciechański
Krystian Ciechański
TCTomasz Chromiński
Tomasz Chromiński
MSMarcin Szczasny
Marcin Szczasny
Andrzej GlowniakAndrzej Glowniak
Andrzej Glowniak